Lysogene: Lysogene Announces Postponement of 2022 Financial Results Release
Regulatory News: Lysogene (FR0013233475 LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that it will not be able to release its 2022 financ...
Read full article »
Lysogene is a France-based biopharmaceutical company that researches and develops gene therapies for the treatment of central nervous system diseases.
Read more